

Amendments to the Claims:

The following claims will replace all prior versions of the claims in this application (in the unlikely event that no claims follow herein, the previously pending claims will remain):

- 1-24. (Cancelled).
- 25. (Currently amended) A compound of the formula [1:

wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be present or is absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁ - C₂₀ acylamine, C₁ - C₂₀ acylexy, C₁ - C₂₀ alkoxycarbonyl, C₁ - C₂₀ alkoxy, C₁ - C₂₀ linear or branched alkylamine, C₁ - C₂₀ alkylearboxylamine, C₁ - C₂₀ carbalkoxy; carboxyl, cyane, brome, chlore, fluore, or hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H.-C₁-C₂₀ acylamino; C₁-C₂₀ aeyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkonyl, C₁-C₂₀ alkonyl, C₁-C₂₀ alkonyl, C₁-C₂₀ alkonyl, C₂-C₂₀ alkonyl, C₃-C₂₀ alkonyl, C₄-C₂₀ alkylamino, C₄-C₂₀ alkylamino, C₄-C₂₀ arabelkoxy; C₆-C₂₀ arabelkoxyl, carboxyl, cyano, brome, chloro, fluoro, or hydroxy; and x and y are independently integers from 0 to 3;

Á

R', R'', and R''' are independently H or G₁—G₂₀ linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C₁—C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₄—G₂₀ acylamino, OH, C₄—G₂₀ alkoxy, halo or cyano: and

X=NH, O, S, S=O, or SO2.

26. (Currently amended) A pharmaceutical composition containing a blood glucose lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier.

wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be present or is absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁–C₂₀ acylamino, C₁–C₂₀ neyloxy, C₁–C₂₀ alkoxycarbonyl, C₁–C₂₀ alkoxy, C₄–C₂₀ linear or branched alkylamino, C₄–C₂₀ alkylearboxylamino, C₄–C₂₀ carbalkoxy; carboxyl, cyano, bromo, chloro, fluoro, or hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H., C_1 . C_{20} acylornino, C_1 . C_{20} acyloxy; C_1 . C_{20} alkenoyl, C_1 . C_{20} alkenoyl, C_1 . C_{20} alkenoyl, C_1 . C_{20} alkoxycarbonyl, C_1 . C_{20} linear or branched alkoxy, C_1 . C_{20} linear or branched alkylamino, C_1 . C_{20} alkylearboxylamino, C_1 . C_{20} carbalkoxy; C_6 . C_{20} are independently integers from 0 to 3;

R', R'', and R''' are independently H or C_1 — C_{20} linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C_1 — C_{20} alkoxycarbonyl, NH₂ CONH₂, C_4 — C_{20} alkoxy, halo or cyano: and

X=NH, O, S, S=O, or SO2.

27. (Currently amended) A method for lowering blood glucose in a subject comprising administering to said subject an effective blood glucose lowering amount of a composition of the formula II.

wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be prosunt or is absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylcarboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, bromo, chloro, fluoro, or hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C_1 , C_{20} acylamino, C_1 , C_{20} acylexy; C_1 , C_{20} alkanoyl, C_1 , C_{20} alkanoyl, C_1 , C_{20} alkanoyl, C_1 , C_{20} alkanoyl, C_1 , C_{20} linear or branched alkoxy, C_1 , C_{20} linear or branched alkylamino, C_1 , C_{20} alkylearboxylamino, C_1 , C_{20} carbalkoxy; C_6 , C_{20} are independently integers from 0 to 3;

R', R'', and R''' are independently H or G_1 - G_{20} linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C_1 - C_{20} alkoxycarbonyl, NH_2 , $CONH_2$, C_1 - C_{20} alkoxy, halo or cyano, and

X=NH, O, S, S=O, or SO2.

28-30. (Withdrawn and cancelled).

31-46. (Cancelled).

47. (Currently amended) A pharmaceutical composition containing a serum triglyceride lowering effective amount of a compound of the formula II in a pharmaceutically acceptable carrier





wherein stereocenters * are R or S;

dotted lines indicate that a double bond may be present or is absent, and the double bond geometry may be £ or 2;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₄-G₂₀ acyloxy, C₁-C₂₀ alkoxycarbonyl, C₄-C₂₀ alkoxy, C₄-C₂₀ linear or branched alkylamino, C₄-C₂₀ alkoxy; carboxyl, cyano, bromo, chlore, fluoro, or hydroxy; and t, u, and w are independently integers from 0 to 3:

B and B' are independently H. C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenyl C₁-C₂₀ alke

 C_{20} linear or branched alkylamino, C_4 - C_{20} alkylearboxylamino, C_4 - C_{20} carbalkoxy, C_6 - C_{20} aroul, C_6 - C_{20} araalkanoyl, carboxyl, cyano, brome, chloro, fluoro, or hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C_1 . C_{20} linear or branched alkyl or alkonyl groups which may contain substituents, COOH, C_1 - C_{20} alkoxycarbonyl, NH₂, CONH₂, C_1 - C_{20} acylamino, OH, C_1 - C_{20} alkoxy, halo or cyano.; and

X = NH, O, S, S=O, or SO₂.

48. (Currently amended) A method for lowering serum triglyceride in a subject comprising administering to said subject an effective serum triglyceride lowering amount of a composition of the formula II.

wherein stereocenters * R or S;

dotted lines indicate that a double bond may be present or is absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ novloxy, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkoxy; carboxyl, cyano, bromo, chloro, fluoro, or hydroxy; and t, u, and w are independently integers from 0 to 3:

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₂-C₂₀ alkenoyl, C₁-C₂₀ alkenoyl, C₂-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylearboxylamino, C₂-C₂₀ carbalkoxy; C₆-C₂₀

aroyl, C₆-C₂₀ araalkanoyl, carboxyl, cyano, bromo, chloro, fluoro, or hydroxy, and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C_1 C₂₀ linear or branched alkyl or alkonyl groups which may contain substituents, COOH, C₁-C₂₀ alkoxycarbonyl, NH₂, CONH₂, C₄-C₂₀-asylamino, OH, C₄ C₃₀-alkoxy, halo or cyano.; and

$$X = NH$$
, O , S , $S=O$, or SO_2 .

49-50. (Withdrawn and cancelled).

51-66. (Cancelled).

67. (Currently amended) A pharmaceutical composition containing a blood pressure lowering effective amount of a compound of the formula ll in a pharmaceutically acceptable carrier.



wherein stereocenters * are R or S:

dotted lines indicate that a double bond may be present or is absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C_1 - C_{24} acylamino, C_1 - C_{20} acyloxy, C_1 - C_{20} alkoxycarbonyl, C_1 - C_{20} alkoxy, C_1 - C_{20} linear or branched alkylamino, C_1 - C_{20} alkylearboxylamino, C_1 - C_{20} carbalkoxy; carboxyl, cyano, bromo, chloro, fluoro, or hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ alkoxycarboxylamino, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylearboxylamino, C₁-C₂₀ carbalkoxy, C₂-C₂₀ aroyl, C₃-C₂₀ araalkanoyl, carboxyl, cyano, bromo, chloro, fluoro, or hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or C_1 - C_{20} linear or branched alkyl or alkenyl groups which may contain substituents, COOH, C_1 - C_{20} alkoxycarbonyl, NH₂, CONH₂, C_1 - C_{20} and anylamino, OH, C_1 - C_{20} alkoxy, halo or cyano: and

 $X = NH_{\bullet}O_{\bullet}S_{\bullet}S = O_{\bullet}O_{\bullet}SO_{\bullet}$

68. (Currently amended) A method for lowering blood pressure in a subject comprising administering to said subject an effective blood pressure lowering amount of a composition of the formula II

wherein stereocenters * are R or S;

dotted lines indicates that a double bond may be present or is absent, and the double bond geometry may be E or Z;

A, A', and C are independently H, C₁-C₂₀ acylamino, C₁-G₂₀-acyloxy, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ alkoxy, C₁-C₂₀ linear or branched alkylamino, C₁-C₂₀ alkylearboxylamino, C₁-C₂₀ carbalkoxy; carboxyl, cyano, bromo, chloro, fluoro, or hydroxy; and t, u, and w are independently integers from 0 to 3;

B and B' are independently H, C₁-C₂₀ acylamino, C₁-C₂₀ acyloxy; C₁-C₂₀ alkanoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkenoyl, C₁-C₂₀ alkoxycarbonyl, C₁-C₂₀ linear or branched alkoxy, C₁-C₂₀ linear or branched alkylamino, C₂-C₂₀ alkylearboxylamino, C₄-C₂₀ carbalkoxy, C₆-C₂₀

aroyl, C_6 C_{20} araalkanoyl, carboxyl, cyane, brome, chlore, fluore, or hydroxy; and x and y are independently integers from 0 to 3;

R', R'', and R''' are independently H or G_1 - G_{20} linear or branched alkyl or alkonyl groups which may contain substituents, COOH, C_1 - C_{20} alkonycarbonyl, NH_2 , $CONH_2$, C_1 - G_{20} acylamino, OH, C_1 - C_{20} alkony, halo or cyano: and

X = NH, O, S, S=O, or SO₂.

69-70. (Withdrawn and cancelled).

- 71. (Cancelled).
- 72. (New) The compound of claim 25 wherein said alkoxycarbonyl is methoxycarbonyl.
- 73. (New) The pharmaceutical composition of claim 26 wherein said alkoxycarbonyl is methoxycarbonyl.
- 74. (New) The method of claim 27 wherein said alkoxycarbonyl is methoxycarbonyl.
- 75. (New) The pharmaceutical composition of claim 47 wherein said alkoxycarbonyl is methoxycarbonyl.
- 76. (New) The method of claim 48 wherein said alkoxycarbonyl is methoxycarbonyl.
- 77. (New) The pharmaceutical composition of claim 67 wherein said alkoxycarbonyl is methoxycarbonyl.
- 78. (New) The method of claim 68 wherein said alkoxycarbonyl is methoxycarbonyl.